Harvard holds on

December 1, 1995

Harvard University still holds a patent for any animal genetically engineered to develop cancer after an appeal against its patent broke up without conclusion last week. Some anti-patent campaigners now predict that Harvard will emerge from the appeal with a restricted patent, for an "onco-rodent".

The appeal was held by the European patent office after objections to Harvard's patent from campaigners across Europe. The appeal will continue in writing.

Please login or register to read this article.

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Register

Have your say

Log in or register to post comments

Most commented

Recent controversy over the future directions of both Stanford and Melbourne university presses have raised questions about the role of in-house publishing arms in a world of commercialisation, impact agendas, alternative facts – and ever-diminishing monograph sales. Anna McKie reports

3 October

Sponsored

Featured jobs